US5723147A
(en)
*
|
1987-02-23 |
1998-03-03 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
US5925375A
(en)
*
|
1987-05-22 |
1999-07-20 |
The Liposome Company, Inc. |
Therapeutic use of multilamellar liposomal prostaglandin formulations
|
US5807572A
(en)
*
|
1988-02-18 |
1998-09-15 |
Depotech Corporation |
Multivesicular liposomes having a biologically active substance encapsulated therein in the presence of a hydrochloride
|
US5169636A
(en)
*
|
1988-03-17 |
1992-12-08 |
Nippon Fine Chemical Co., Ltd. |
Liposomes
|
US5422120A
(en)
*
|
1988-05-30 |
1995-06-06 |
Depotech Corporation |
Heterovesicular liposomes
|
US5230900A
(en)
*
|
1988-07-01 |
1993-07-27 |
The Biomembrane Institute |
Antibody-mediated and ligand-mediated targeting of differentiation-inducers to tumor cells
|
JPH0720857B2
(ja)
*
|
1988-08-11 |
1995-03-08 |
テルモ株式会社 |
リポソームおよびその製法
|
GB8824593D0
(en)
*
|
1988-10-20 |
1988-11-23 |
Royal Free Hosp School Med |
Liposomes
|
US5043164A
(en)
*
|
1989-01-17 |
1991-08-27 |
The University Of Tennessee Research Corporation |
Blood-stable, cholesterol-free liposomes
|
US5013556A
(en)
*
|
1989-10-20 |
1991-05-07 |
Liposome Technology, Inc. |
Liposomes with enhanced circulation time
|
US5356633A
(en)
*
|
1989-10-20 |
1994-10-18 |
Liposome Technology, Inc. |
Method of treatment of inflamed tissues
|
US5843473A
(en)
*
|
1989-10-20 |
1998-12-01 |
Sequus Pharmaceuticals, Inc. |
Method of treatment of infected tissues
|
JP2785981B2
(ja)
*
|
1989-11-20 |
1998-08-13 |
株式会社資生堂 |
乳化組成物
|
US5053406A
(en)
*
|
1989-12-13 |
1991-10-01 |
Glycomed, Inc. |
Compositions and methods for preventing and treating rotaviral infections
|
US5882678A
(en)
*
|
1990-01-12 |
1999-03-16 |
The Liposome Co, Inc. |
Interdigitation-fusion liposomes containing arachidonic acid metabolites
|
US5162361A
(en)
*
|
1990-04-10 |
1992-11-10 |
The United States Of America As Represented By The Secretary, Department Of Health And Human Services |
Method of treating diseases associated with elevated levels of interleukin 1
|
FR2661331A1
(fr)
*
|
1990-04-30 |
1991-10-31 |
Oreal |
Composition cosmetique ou dermopharmaceutique contenant des vesicules formees par un melange phospholipides/glycolipides.
|
DE4107152C2
(de)
*
|
1991-03-06 |
1994-03-24 |
Gregor Cevc |
Präparate zur nichtinvasiven Verabreichung von Antidiabetica
|
DE4107153A1
(de)
*
|
1991-03-06 |
1992-09-10 |
Gregor Cevc |
Praeparat zur wirkstoffapplikation in kleinsttroepfchenform
|
US5298246A
(en)
*
|
1991-01-09 |
1994-03-29 |
Kanegafuchi Kagaku Kogyo Kabushiki Kaisha |
Stable pharmaceutical composition and method for its production
|
CA2120507A1
(en)
*
|
1991-10-18 |
1993-04-29 |
Alban J. Linnenbach |
Soluble variants of type 1 membrane proteins, and methods of using them
|
US5858399A
(en)
*
|
1992-04-09 |
1999-01-12 |
Northwestern University |
Acoustically reflective liposomes and methods to make and use the same
|
WO1993020802A1
(en)
*
|
1992-04-09 |
1993-10-28 |
Northwestern University |
Acoustically reflective liposomes and methods to make and use the same
|
EP0728476B1
(de)
*
|
1992-04-10 |
2002-09-04 |
Hisamitsu Pharmaceutical Co., Inc. |
Liposomenzusammensetzung
|
US5455044A
(en)
*
|
1993-05-14 |
1995-10-03 |
Depotech Corporation |
Method for treating neurological disorders
|
US5534241A
(en)
*
|
1993-07-23 |
1996-07-09 |
Torchilin; Vladimir P. |
Amphipathic polychelating compounds and methods of use
|
US5863556A
(en)
*
|
1993-08-20 |
1999-01-26 |
Euro-Celtique, S.A. |
Preparations for the external application of antiseptic agents and/or agents promoting the healing of wounds
|
US6217849B1
(en)
|
1993-09-29 |
2001-04-17 |
Bracco Research S.A. |
Liposome suspensions as blood pool imaging contrast agents
|
PT725629E
(pt)
*
|
1993-10-25 |
2000-11-30 |
Liposome Co Inc |
Defensinas em lipossomas
|
US5468499A
(en)
*
|
1993-11-15 |
1995-11-21 |
Ohio State University |
Liposomes containing the salt of phosphoramide mustard and related compounds
|
DK0729351T3
(da)
*
|
1993-11-16 |
2000-10-16 |
Skyepharma Inc |
Vesikler med reguleret afgivelse af aktivstoffer
|
FR2712811B1
(fr)
*
|
1993-11-26 |
1996-01-05 |
Oreal |
Procédé pour lutter contre l'adiposite et compositions utilisables à cet effet.
|
US5543152A
(en)
*
|
1994-06-20 |
1996-08-06 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
US5741516A
(en)
*
|
1994-06-20 |
1998-04-21 |
Inex Pharmaceuticals Corporation |
Sphingosomes for enhanced drug delivery
|
US5993850A
(en)
*
|
1994-09-13 |
1999-11-30 |
Skyepharma Inc. |
Preparation of multivesicular liposomes for controlled release of encapsulated biologically active substances
|
US5885613A
(en)
*
|
1994-09-30 |
1999-03-23 |
The University Of British Columbia |
Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
|
US5820873A
(en)
*
|
1994-09-30 |
1998-10-13 |
The University Of British Columbia |
Polyethylene glycol modified ceramide lipids and liposome uses thereof
|
PT785773E
(pt)
*
|
1994-10-14 |
2001-05-31 |
Liposome Co Inc |
Lipossomas de eteres lipidicos e sua utilizacao terapeutica
|
EP0759785B1
(de)
*
|
1995-02-24 |
2001-10-31 |
Bracco Research S.A. |
Liposomensuspensionen als blut-pool-kontrastmittel
|
US6358915B1
(en)
*
|
1995-03-07 |
2002-03-19 |
George Washington University |
Methods for inhibiting metastasis
|
US6184201B1
(en)
*
|
1995-04-14 |
2001-02-06 |
Nps Allelix Corp. |
Intestinotrophic glucagon-like peptide-2 analogs
|
US5834428A
(en)
*
|
1995-04-14 |
1998-11-10 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
US6673364B1
(en)
|
1995-06-07 |
2004-01-06 |
The University Of British Columbia |
Liposome having an exchangeable component
|
US5931809A
(en)
*
|
1995-07-14 |
1999-08-03 |
Depotech Corporation |
Epidural administration of therapeutic compounds with sustained rate of release
|
US5855911A
(en)
*
|
1995-08-29 |
1999-01-05 |
Board Of Regents, The University Of Texas System |
Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
|
US6107332A
(en)
|
1995-09-12 |
2000-08-22 |
The Liposome Company, Inc. |
Hydrolysis-promoting hydrophobic taxane derivatives
|
US6051600A
(en)
*
|
1995-09-12 |
2000-04-18 |
Mayhew; Eric |
Liposomal hydrolysis-promoting hydrophobic taxane derivatives
|
US6153736A
(en)
*
|
1995-09-27 |
2000-11-28 |
The Liposome Company, Inc. |
Modified ether glyceroglycolipids
|
US5834025A
(en)
*
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
US5942246A
(en)
*
|
1996-02-16 |
1999-08-24 |
The Liposome Company, Inc. |
Etherlipid containing multiple lipid liposomes
|
US6667053B1
(en)
|
1996-02-16 |
2003-12-23 |
Elan Pharmaceuticals, Inc. |
D and L etherlipid stereoisomers and liposomes
|
US6007839A
(en)
*
|
1996-02-16 |
1999-12-28 |
The Liposome Company, Inc. |
Preparation of pharmaceutical compositions containing etherlipid-containing multiple lipid liposomes
|
USRE39042E1
(en)
*
|
1996-02-16 |
2006-03-28 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
US5965159A
(en)
|
1996-02-16 |
1999-10-12 |
The Liposome Company, Inc. |
Etherlipid-containing multiple lipid liposomes
|
WO1997035560A1
(en)
|
1996-03-28 |
1997-10-02 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved echogenic liposome compositions
|
EP2275438A1
(de)
|
1996-04-12 |
2011-01-19 |
1149336 Ontario Inc. |
Analoge des Glucagon ähnlichen Peptides-2
|
AU5571196A
(en)
*
|
1996-04-24 |
1997-11-12 |
Sdg, Inc. |
Improved masking of liposomes from res recognition
|
US6111081A
(en)
*
|
1996-05-31 |
2000-08-29 |
Baylor College Of Medicine |
Lactoferrin variants and uses thereof
|
US7309692B1
(en)
*
|
1996-07-08 |
2007-12-18 |
Board Of Regents, The University Of Texas System |
Inhibition of chronic myelogenous leukemic cell growth by liposomal-antisense oligodeoxy-nucleotides targeting to GRB2 or CRK1
|
US7368129B1
(en)
|
1996-08-14 |
2008-05-06 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
US6284267B1
(en)
|
1996-08-14 |
2001-09-04 |
Nutrimed Biotech |
Amphiphilic materials and liposome formulations thereof
|
KR100190826B1
(ko)
*
|
1996-08-26 |
1999-06-01 |
강재헌 |
적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법
|
US5997899A
(en)
|
1996-10-01 |
1999-12-07 |
Skyepharma Inc. |
Method for producing liposomes with increased percent of compound encapsulated
|
US6977244B2
(en)
|
1996-10-04 |
2005-12-20 |
Board Of Regents, The University Of Texas Systems |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6339069B1
(en)
|
1996-10-15 |
2002-01-15 |
Elan Pharmaceuticalstechnologies, Inc. |
Peptide-lipid conjugates, liposomes and lipsomal drug delivery
|
NZ336539A
(en)
*
|
1996-10-15 |
2000-09-29 |
Liposome Co Inc |
Peptide-lipid conjugates, liposomes and liposomal drug delivery
|
US6037125A
(en)
*
|
1996-11-05 |
2000-03-14 |
Lexicon Genetics Incorporated |
Disruption of the mammalian RAD51 protein and disruption of proteins that associate with mammalian RAD51 for hindering cell proliferation and/or viability of proliferating cells
|
US5827533A
(en)
|
1997-02-06 |
1998-10-27 |
Duke University |
Liposomes containing active agents aggregated with lipid surfactants
|
US6123956A
(en)
*
|
1997-07-10 |
2000-09-26 |
Keith Baker |
Methods for universally distributing therapeutic agents to the brain
|
US20050025819A1
(en)
*
|
1997-07-14 |
2005-02-03 |
Hayat Onyuksel |
Materials and methods for making improved micelle compositions
|
US20020115609A1
(en)
*
|
1997-07-14 |
2002-08-22 |
Hayat Onyuksel |
Materials and methods for making improved micelle compositions
|
US6217886B1
(en)
|
1997-07-14 |
2001-04-17 |
The Board Of Trustees Of The University Of Illinois |
Materials and methods for making improved micelle compositions
|
US6306432B1
(en)
|
1997-09-08 |
2001-10-23 |
Chiron Corporation |
High and low load formulations of IGF-I in multivesicular liposomes
|
EP2198854B1
(de)
|
1997-09-18 |
2011-11-30 |
Pacira Pharmaceuticals, Inc. |
Retardierte Freisetzung Liposomaler Anesthetischer Zusammensetzungen
|
US7704962B1
(en)
|
1997-10-03 |
2010-04-27 |
Board Of Regents, The University Of Texas System |
Small oligonucleotides with anti-tumor activity
|
US7285288B1
(en)
|
1997-10-03 |
2007-10-23 |
Board Of Regents, The University Of Texas System |
Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
|
US6734171B1
(en)
|
1997-10-10 |
2004-05-11 |
Inex Pharmaceuticals Corp. |
Methods for encapsulating nucleic acids in lipid bilayers
|
US20020039596A1
(en)
*
|
1997-11-14 |
2002-04-04 |
Hartoun Hartounian |
Production of multivesicular liposomes
|
US7098192B2
(en)
|
1999-04-08 |
2006-08-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of STAT3 expression
|
EP1190705A4
(de)
*
|
1999-06-24 |
2009-03-18 |
Kyowa Hakko Kogyo Kk |
Verfahren zur regulation des herausdiffundierens von in liposomen verkapseltem arzneistoff
|
GB9918670D0
(en)
|
1999-08-06 |
1999-10-13 |
Celltech Therapeutics Ltd |
Biological product
|
MXPA02006121A
(es)
*
|
1999-12-30 |
2004-08-23 |
Judith K Gwathemy |
Sistema de suministro de formador de quelatos de hierro.
|
US20020055479A1
(en)
|
2000-01-18 |
2002-05-09 |
Cowsert Lex M. |
Antisense modulation of PTP1B expression
|
US6261840B1
(en)
|
2000-01-18 |
2001-07-17 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of PTP1B expression
|
AU2001247244B2
(en)
*
|
2000-02-28 |
2005-06-02 |
Genesegues, Inc. |
Nanocapsule encapsulation system and method
|
EP1263484B1
(de)
|
2000-03-15 |
2007-05-16 |
OrbusNeich Medical, Inc. |
Beschichtung welche ein anhaften von endothelzellen stimuliert
|
US9522217B2
(en)
|
2000-03-15 |
2016-12-20 |
Orbusneich Medical, Inc. |
Medical device with coating for capturing genetically-altered cells and methods for using same
|
US20070141107A1
(en)
*
|
2000-03-15 |
2007-06-21 |
Orbusneich Medical, Inc. |
Progenitor Endothelial Cell Capturing with a Drug Eluting Implantable Medical Device
|
US8088060B2
(en)
|
2000-03-15 |
2012-01-03 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
US20030229393A1
(en)
*
|
2001-03-15 |
2003-12-11 |
Kutryk Michael J. B. |
Medical device with coating that promotes cell adherence and differentiation
|
US20070055367A1
(en)
*
|
2000-03-15 |
2007-03-08 |
Orbus Medical Technologies, Inc. |
Medical device with coating that promotes endothelial cell adherence and differentiation
|
US8460367B2
(en)
*
|
2000-03-15 |
2013-06-11 |
Orbusneich Medical, Inc. |
Progenitor endothelial cell capturing with a drug eluting implantable medical device
|
US6613748B2
(en)
|
2000-12-11 |
2003-09-02 |
The Research Foundation Of The City University Of New York |
C-glucosyl ether lipids
|
US8658202B2
(en)
|
2001-04-25 |
2014-02-25 |
Western University Of Health Sciences |
Coated drug delivery formulations
|
US6759058B1
(en)
*
|
2001-04-25 |
2004-07-06 |
Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences |
Enteric-coated proliposomal formulations for poorly water soluble drugs
|
EP2270024B1
(de)
|
2001-06-21 |
2018-10-24 |
Ionis Pharmaceuticals, Inc. |
Antisense-Modulation von Superoxid-Dismutase 1, Expression in Lösung
|
US6964950B2
(en)
|
2001-07-25 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of C-reactive protein expression
|
US20030096772A1
(en)
|
2001-07-30 |
2003-05-22 |
Crooke Rosanne M. |
Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
|
US7407943B2
(en)
|
2001-08-01 |
2008-08-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein B expression
|
US7227014B2
(en)
|
2001-08-07 |
2007-06-05 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of apolipoprotein (a) expression
|
ATE516364T1
(de)
|
2001-10-09 |
2011-07-15 |
Isis Pharmaceuticals Inc |
Antisense-modulation der expression des insulinähnlicher-wachstumsfaktor-bindungsprotei s 5
|
US6750019B2
(en)
|
2001-10-09 |
2004-06-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of insulin-like growth factor binding protein 5 expression
|
ATE390121T1
(de)
*
|
2001-11-02 |
2008-04-15 |
Univ Alberta |
Micelle-zusammensetzungen enthaltend pegylierten phospholipide und einen photosensibilisator
|
US6965025B2
(en)
|
2001-12-10 |
2005-11-15 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of connective tissue growth factor expression
|
EP1460898A4
(de)
*
|
2002-01-03 |
2006-05-24 |
Univ Texas |
Wt1-antisense-oligos für die hemmung von brustkrebs
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
WO2003087368A2
(en)
*
|
2002-04-18 |
2003-10-23 |
Lynkeus Bio Tech Gmbh |
Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification
|
US7148342B2
(en)
|
2002-07-24 |
2006-12-12 |
The Trustees Of The University Of Pennyslvania |
Compositions and methods for sirna inhibition of angiogenesis
|
US20040213837A1
(en)
*
|
2002-08-05 |
2004-10-28 |
Sankaram Mantripragada |
Oil-core compositions for the sustained release of hydrophobic drugs
|
BR0314236A
(pt)
|
2002-09-13 |
2005-08-09 |
Replicor Inc |
Formulação de oligonucleotìdeo, composição farmacêutica, kit, composto antiviral, preparação de oligonucleotìdeo e métodos para seleção de um oligonucleotìdeo antiviral para uso como um agente antiviral, para profilaxia ou tratamento de uma infecção viral em um paciente, para tratamento profilático de câncer causado por oncovìrus, para identificação de um composto que altera a ligação de um oligonucleotìdeo a pelo menos um componente viral, para purificação da ligação de oligonucleotìdeos a pelo menos um componente viral e para enriquecimento de oligonucleotìdeos a partir de um agrupamento de oligonucleotìdeos
|
WO2004031350A2
(en)
|
2002-09-26 |
2004-04-15 |
Amgen, Inc. |
Modulation of forkhead box o1a expression
|
EP2336318B1
(de)
|
2002-11-13 |
2013-04-24 |
Genzyme Corporation |
Antisense-modulation von apolipoprotein-b-expression
|
ES2417879T3
(es)
|
2002-11-13 |
2013-08-09 |
Genzyme Corporation |
Modulación antisentido de la expresión de la apolipoproteína B
|
DE60330745D1
(de)
|
2002-12-31 |
2010-02-11 |
Bharat Serums & Vaccines Ltd |
Nicht-pegylierte lang-zirkulierende Liposome
|
US8980310B2
(en)
*
|
2002-12-31 |
2015-03-17 |
Bharat Serums and Vaccines, Ltd. |
Non-pegylated long-circulating liposomes
|
DE602004028587D1
(de)
|
2003-01-16 |
2010-09-23 |
Univ Pennsylvania |
ZUSAMMENSETZUNGEN UND VERFAHREN ZUR siRNA-HEMMUNG VON ICAM-1
|
US7825235B2
(en)
|
2003-08-18 |
2010-11-02 |
Isis Pharmaceuticals, Inc. |
Modulation of diacylglycerol acyltransferase 2 expression
|
US7579455B2
(en)
*
|
2003-09-29 |
2009-08-25 |
Topigen Pharmaceutique Inc. |
Oligonucleotide compositions and methods for treating disease including inflammatory conditions
|
US7960350B2
(en)
|
2003-10-24 |
2011-06-14 |
Ader Enterprises, Inc. |
Composition and method for the treatment of eye disease
|
EP2295604B1
(de)
|
2004-02-09 |
2015-04-08 |
Thomas Jefferson University |
Krebsdiagnose und Behandlung durch microRNA, die sich in der Nähe von Krebs-verbindenen Chromosom-Merkmale befinden
|
KR20070008714A
(ko)
*
|
2004-04-30 |
2007-01-17 |
오르버스네이치 메디칼 인코포레이티드 |
유전적으로-변형된 세포 포획용 코팅을 갖는 의료 장치 및이의 사용 방법
|
US7749485B2
(en)
*
|
2004-06-03 |
2010-07-06 |
Bracco Research S.A. |
Liposomal assembly for therapeutic and/or diagnostic use
|
WO2006047394A1
(en)
*
|
2004-10-22 |
2006-05-04 |
Benitec, Inc. |
Therapeutic rnai agents for treating psoriasis
|
WO2006045202A1
(en)
*
|
2004-10-29 |
2006-05-04 |
Topigen Pharmaceuticals Inc. |
Antisense oligonucleotides for treating allergy and neoplastic cell proliferation
|
WO2006052767A2
(en)
*
|
2004-11-05 |
2006-05-18 |
Inex Pharmaceuticals Corporation |
Compositions and methods for stabilizing liposomal camptothecin formulations
|
CA2605863C
(en)
*
|
2005-04-29 |
2016-07-05 |
University Of Louisville Research Foundation, Inc. |
Cell-surface decoration with active agents
|
WO2006135785A2
(en)
*
|
2005-06-10 |
2006-12-21 |
Medical College Of Georgia Research Institute |
Compositions and methods for treating immune disorders
|
US9446017B2
(en)
|
2005-08-11 |
2016-09-20 |
Augusta University Research Institute, Inc. |
Compositions and methods for treating herpes simplex virus
|
CN103028120B
(zh)
|
2005-09-12 |
2015-08-12 |
俄亥俄州立大学研究基金会 |
用于诊断或治疗bcl2相关癌症的组合物和方法
|
US7700567B2
(en)
|
2005-09-29 |
2010-04-20 |
Supergen, Inc. |
Oligonucleotide analogues incorporating 5-aza-cytosine therein
|
US20070197460A1
(en)
|
2005-11-01 |
2007-08-23 |
Alnylam Pharmaceuticals, Inc. |
Rnai inhibition of influenza virus replication
|
WO2007070705A2
(en)
*
|
2005-12-15 |
2007-06-21 |
The Trustees Of The University Of Pennsylvania |
Cationic lipid-mediated vectors
|
EP2221378B1
(de)
|
2005-12-22 |
2013-04-17 |
OPKO Pharmaceuticals, LLC |
Zusammensetzungen und Verfahren zur Regulierung eines Komplementsystems
|
ES2553442T3
(es)
|
2006-01-05 |
2015-12-09 |
The Ohio State University Research Foundation |
Procedimientos basados en los microARN para el diagnóstico, pronóstico y tratamiento del cáncer de pulmón
|
CN101384273B
(zh)
|
2006-01-05 |
2013-07-10 |
俄亥俄州立大学研究基金会 |
胰腺内分泌和腺泡肿瘤中的微小rna表达异常
|
US8148069B2
(en)
|
2006-01-05 |
2012-04-03 |
The Ohio State University |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of solid cancers
|
EP1991706B1
(de)
|
2006-03-02 |
2014-01-15 |
The Ohio State University Research Foundation |
Mikro-rna-expressionsprofil im zusammenhang mit bauchspeicheldrüsenkrebs
|
ES2446362T3
(es)
|
2006-03-20 |
2014-03-07 |
The Ohio State University Research Foundation |
Huellas de microARN durante megacariocipoyesis humana
|
WO2007117469A2
(en)
|
2006-03-30 |
2007-10-18 |
The Research Foundation Of State University Of New York |
Compositions of less immunogenic and long-circulating protein-lipid complexes
|
WO2007123691A2
(en)
*
|
2006-03-30 |
2007-11-01 |
The Research Foundation Of State University Of New York |
Method for treating blood coagulation disorders
|
US7875288B2
(en)
*
|
2006-03-30 |
2011-01-25 |
The Research Foundation Of State University Of New York |
Method for treating blood coagulation disorders
|
NZ587704A
(en)
|
2006-03-31 |
2012-04-27 |
Alnylam Pharmaceuticals Inc |
Use of dsRNA for inhibiting expression of Eg5 gene
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
WO2007133758A1
(en)
*
|
2006-05-15 |
2007-11-22 |
Physical Pharmaceutica, Llc |
Composition and improved method for preparation of small particles
|
CN101448847A
(zh)
*
|
2006-05-19 |
2009-06-03 |
托皮根药品公司 |
影响磷酸二酯酶表达的寡核苷酸
|
WO2007137156A2
(en)
|
2006-05-19 |
2007-11-29 |
Alnylam Pharmaceuticals, Inc. |
Rnai modulation of aha and therapeutic uses thereof
|
CA2653451C
(en)
|
2006-05-22 |
2015-12-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of ikk-b gene
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
DK2029746T3
(da)
*
|
2006-06-12 |
2012-10-08 |
Exegenics Inc D B A Opko Health Inc |
Sammensætninger og fremgangsmåder til siRNA-hæmning af angiogenese
|
ES2434075T3
(es)
|
2006-07-13 |
2013-12-13 |
The Ohio State University Research Foundation |
MIR-203 para el diagnóstico de adenocarcinoma de colon con mal pronóstico de supervivencia
|
US7872118B2
(en)
*
|
2006-09-08 |
2011-01-18 |
Opko Ophthalmics, Llc |
siRNA and methods of manufacture
|
US8048998B2
(en)
|
2007-01-19 |
2011-11-01 |
Exiqon A/S |
Mediated cellular delivery of LNA oligonucleotides
|
WO2008091655A2
(en)
*
|
2007-01-23 |
2008-07-31 |
The Regents Of The University Of California |
Methods, compositions and device for directed and controlled heating and release of agents
|
AP3018A
(en)
|
2007-03-29 |
2014-10-31 |
Alnylam Pharmaceuticals Inc |
Compositions and methods for inhibiting expressionof a gene from the ebola
|
AR066984A1
(es)
|
2007-06-15 |
2009-09-23 |
Novartis Ag |
Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
|
CA2692171C
(en)
|
2007-06-22 |
2019-10-22 |
Randolph Watnick |
Methods and uses thereof of prosaposin
|
US7910722B2
(en)
|
2007-07-05 |
2011-03-22 |
Florida State University Research Foundation |
RNAi therapeutic for treatment of hepatitis C infection
|
ES2496172T3
(es)
|
2007-07-31 |
2014-09-18 |
The Ohio State University Research Foundation |
Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B
|
US8465918B2
(en)
|
2007-08-03 |
2013-06-18 |
The Ohio State University Research Foundation |
Ultraconserved regions encoding ncRNAs
|
US7960336B2
(en)
|
2007-08-03 |
2011-06-14 |
Pharmain Corporation |
Composition for long-acting peptide analogs
|
WO2009023025A1
(en)
*
|
2007-08-13 |
2009-02-19 |
Board Of Trustees Of Southern Illinois University |
Methods for treatment and prevention of ototoxicity by sirna
|
US8466119B2
(en)
|
2007-08-22 |
2013-06-18 |
The Ohio State University Research Foundation |
Methods and compositions for inducing deregulation of EPHA7 and ERK phosphorylation in human acute leukemias
|
WO2009033140A1
(en)
|
2007-09-06 |
2009-03-12 |
The Ohio State University Research Foundation |
Microrna signatures in human ovarian cancer
|
ES2588705T3
(es)
|
2007-09-27 |
2016-11-04 |
Immunovaccine Technologies Inc. |
Uso de liposomas en un vehículo que comprende una fase hidrófoba continua para la entrega de polinucleótidos in vivo
|
US20100209452A1
(en)
*
|
2007-10-03 |
2010-08-19 |
Immunovaccine Technologies, Inc |
Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
|
EP2212440A4
(de)
|
2007-10-11 |
2011-04-06 |
Univ Ohio State Res Found |
Verfahren und zusammensetzungen zur diagnose und behandlung von adenokarzinomen der speiseröhre
|
EP2617828B1
(de)
|
2007-12-10 |
2014-09-24 |
Alnylam Pharmaceuticals Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Faktor VII-Genexpression
|
EP2712926A2
(de)
|
2008-03-05 |
2014-04-02 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Eg5- und des VEGF-Gens
|
US8314068B2
(en)
|
2008-04-14 |
2012-11-20 |
University Hospitals Of Cleveland |
P2X7 inhibition of epithelial cancers and papillomas
|
AU2009246000B2
(en)
|
2008-05-15 |
2014-09-04 |
Topigen Pharmaceuticals Inc. |
Oligonucleotides for treating inflammation and neoplastic cell proliferation
|
US20110070298A1
(en)
|
2008-06-05 |
2011-03-24 |
Immunovaccine Technologies Inc. |
Compositions Comprising Liposomes, An Antigen, A Polynucleotide and A Carrier Comprising a Continuous Phase of a Hydrophobic Substance
|
DK2331141T3
(en)
|
2008-08-25 |
2016-04-04 |
Excaliard Pharmaceuticals Inc |
Antisense oligonucleotides WHO IS TARGETING connective tissue, AND USES THEREOF
|
EP2329044B1
(de)
|
2008-08-27 |
2016-05-18 |
Oncotherapy Science, Inc. |
Prmt1 für zielgene zur krebstherapie und -diagnose
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
CN102224254A
(zh)
|
2008-09-23 |
2011-10-19 |
哈佛大学校长及研究员协会 |
Sirt4及其用途
|
JP5529142B2
(ja)
|
2008-09-25 |
2014-06-25 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
血清アミロイドa遺伝子の発現を阻害するための脂質製剤組成物および方法
|
SI2937418T1
(en)
|
2008-10-20 |
2018-02-28 |
Alnylam Pharmaceuticals, Inc. |
Compounds and procedures for inhibiting the expression of transthyretin
|
CA2745832A1
(en)
|
2008-12-04 |
2010-06-10 |
Opko Ophthalmics, Llc |
Compositions and methods for selective inhibition of pro-angiogenic vegf isoforms
|
JP5855462B2
(ja)
|
2008-12-10 |
2016-02-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
GNAQを標的としたdsRNA組成物および発現を阻害するための方法
|
US8492133B2
(en)
|
2009-01-20 |
2013-07-23 |
Ramot At Tel Aviv University, Ltd. |
MIR-21 promoter driven targeted cancer therapy
|
US20120041051A1
(en)
|
2009-02-26 |
2012-02-16 |
Kevin Fitzgerald |
Compositions And Methods For Inhibiting Expression Of MIG-12 Gene
|
WO2010105209A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
|
US8524784B2
(en)
*
|
2009-04-30 |
2013-09-03 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
WO2010127271A1
(en)
|
2009-04-30 |
2010-11-04 |
Intezyne Technologies, Incorporated |
Polymer micelles containing anthracylines for the treatment of cancer
|
IT1398857B1
(it)
|
2009-06-10 |
2013-03-21 |
Univ Padova |
Coniugati polimerici fosfolipidi
|
US9029338B2
(en)
|
2009-08-14 |
2015-05-12 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
|
AU2010288810A1
(en)
|
2009-08-31 |
2012-03-01 |
University Of Bremen |
MicroRNA-based methods and compositions for the diagnosis, prognosis and treatment of tumor involving chromosomal rearrangements
|
BR112012007160A2
(pt)
|
2009-09-30 |
2018-03-13 |
Harvard College |
metodos para modulacao da autofagia por meio da modulacao d eprodutos genicos inibidores da autofagia
|
EP2488210A4
(de)
|
2009-10-12 |
2014-04-30 |
Smith Holdings Llc |
Verfahren und zusammensetzungen zur modulation der genexpression mit in-vivo oder in-vitro verabreichten arzneistoffen auf oligonukleotidbasis
|
ES2632431T3
(es)
|
2009-10-30 |
2017-09-13 |
Ntf Therapeutics, Inc. |
Moléculas de neurturina mejoradas
|
ES2713852T3
(es)
|
2009-12-01 |
2019-05-24 |
Translate Bio Inc |
Derivado de esteroides para la administración de ARNm en enfermedades genéticas humanas
|
WO2011069155A1
(en)
*
|
2009-12-04 |
2011-06-09 |
Opko Ophthalmics, Llc |
Compositions and methods for inhibition of vegf
|
EP3925670A1
(de)
|
2009-12-17 |
2021-12-22 |
Children's Medical Center, Corp. |
Aus saposin-a gewonnene peptide und verwendungen davon
|
US20130195961A1
(en)
|
2010-03-09 |
2013-08-01 |
Kejian Yang |
Novel mucosal vaccination approach for herpes simplex virus type-2
|
ES2893199T3
(es)
|
2010-03-29 |
2022-02-08 |
Alnylam Pharmaceuticals Inc |
Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
|
US9168288B2
(en)
|
2010-04-09 |
2015-10-27 |
Mount Sinai Hospital |
Methods for treating disorders of the gastrointestinal tract using a GLP-1 agonist
|
JP6081910B2
(ja)
|
2010-06-02 |
2017-02-15 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
肝線維症治療用組成物および肝線維症の治療法
|
WO2012006552A1
(en)
|
2010-07-09 |
2012-01-12 |
Exelixis, Inc. |
Combinations of kinase inhibitors for the treatment of cancer
|
WO2012064824A1
(en)
|
2010-11-09 |
2012-05-18 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
WO2012068463A2
(en)
|
2010-11-18 |
2012-05-24 |
Beth Israel Deaconess Medicall Center, Inc. |
Methods of treating obesity by inhibiting nicotinamide n-methyl transferase (nnmt)
|
US8853377B2
(en)
|
2010-11-30 |
2014-10-07 |
Shire Human Genetic Therapies, Inc. |
mRNA for use in treatment of human genetic diseases
|
WO2012075337A2
(en)
|
2010-12-01 |
2012-06-07 |
Spinal Modulation, Inc. |
Directed delivery of agents to neural anatomy
|
WO2012078967A2
(en)
|
2010-12-10 |
2012-06-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for increasing erythropoietin (epo) production
|
EP2648763A4
(de)
|
2010-12-10 |
2014-05-14 |
Alnylam Pharmaceuticals Inc |
Zusammensetzungen und verfahren zur expressionshemmung der gene klf-1 und bcl11a
|
AU2012212110A1
(en)
|
2011-02-02 |
2013-08-01 |
Excaliard Pharmaceuticals, Inc. |
Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (CTGF)
|
KR102104401B1
(ko)
|
2011-03-29 |
2020-04-27 |
알닐람 파마슈티칼스 인코포레이티드 |
Tmprss6 유전자의 발현을 억제하기 위한 조성물 및 방법
|
WO2012164058A1
(en)
|
2011-06-01 |
2012-12-06 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for adjusting expression of mitochondrial genome by microrna
|
JP6662566B2
(ja)
|
2011-06-02 |
2020-03-11 |
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ |
エキソビボ組織培養システムのための方法および使用
|
CA2838063C
(en)
|
2011-06-08 |
2023-07-11 |
Shire Human Genetic Therapies, Inc. |
Cleavable lipids
|
KR20200084048A
(ko)
|
2011-06-08 |
2020-07-09 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Mrna 전달을 위한 지질 나노입자 조성물 및 방법
|
AU2012271413B2
(en)
|
2011-06-17 |
2017-07-13 |
President And Fellows Of Harvard College |
Frizzled 2 as a target for therapeutic antibodies in the treatment of cancer
|
RU2631805C2
(ru)
|
2011-06-21 |
2017-09-26 |
Элнилэм Фармасьютикалз, Инк. |
Композиции и способы ингибирования экспрессии генов аполипопротеина с-iii (арос3)
|
AU2012272908A1
(en)
|
2011-06-21 |
2013-12-19 |
Alnylam Pharmaceuticals, Inc. |
Assays and methods for determining activity of a therapeutic agent in a subject
|
AU2012272970A1
(en)
|
2011-06-21 |
2014-02-06 |
Alnylam Pharmaceuticals, Inc. |
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
|
EP3388068A1
(de)
|
2011-06-21 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzung und verfahren zur hemmung der expression von protein-c (proc)-genen
|
WO2012178033A2
(en)
|
2011-06-23 |
2012-12-27 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 sirnas: compositions of matter and methods of treatment
|
AU2012275841A1
(en)
|
2011-06-27 |
2014-01-16 |
The Jackson Laboratory |
Methods and compositions for treatment of cancer and autoimmune disease
|
EP2543370A1
(de)
|
2011-07-06 |
2013-01-09 |
Georgia Health Sciences University Research Institute, Inc. |
Zusammensetzungen und Verfahren zur Behandlung des Herpes-simplex-Virus
|
US10323236B2
(en)
|
2011-07-22 |
2019-06-18 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
JP2014526887A
(ja)
|
2011-08-01 |
2014-10-09 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
造血幹細胞移植の成功率を改善する方法
|
AU2012321022B2
(en)
|
2011-10-06 |
2017-03-23 |
Immunovaccine Technologies Inc. |
Liposome compositions comprising an adjuvant that activates or increases the activity of TLR2 and uses thereof
|
EP2766500A4
(de)
|
2011-10-14 |
2015-10-14 |
Univ Ohio State |
Verfahren und materialien in verbindung mit eierstockkrebs
|
WO2013060894A1
(en)
|
2011-10-27 |
2013-05-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of atherosclerosis
|
WO2013096868A2
(en)
|
2011-12-22 |
2013-06-27 |
Children's Medical Center Corporation |
Saposin-a derived peptides and uses thereof
|
US9737480B2
(en)
|
2012-02-06 |
2017-08-22 |
President And Fellows Of Harvard College |
ARRDC1-mediated microvesicles (ARMMs) and uses thereof
|
WO2013149140A1
(en)
|
2012-03-29 |
2013-10-03 |
Shire Human Genetic Therapies, Inc. |
Ionizable cationic lipids
|
JP6492003B2
(ja)
|
2012-03-30 |
2019-03-27 |
ワシントン・ユニバーシティWashington University |
発作を減少させるためおよび神経変性症候群を改質するためにタウ発現を調節する方法
|
US9133461B2
(en)
|
2012-04-10 |
2015-09-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the ALAS1 gene
|
JP2015518475A
(ja)
|
2012-04-10 |
2015-07-02 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラルシェルシェ メディカル)Inserm(Institut National Dela Sante Etde La Recherche Medicale) |
非アルコール性脂肪性肝炎の治療方法
|
WO2013153139A1
(en)
|
2012-04-11 |
2013-10-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment and diagnosis of acute leukemia
|
US9127274B2
(en)
|
2012-04-26 |
2015-09-08 |
Alnylam Pharmaceuticals, Inc. |
Serpinc1 iRNA compositions and methods of use thereof
|
EP2859102A4
(de)
|
2012-06-08 |
2016-05-11 |
Shire Human Genetic Therapies |
Nukleaseresistente polynukleotide und verwendungen davon
|
KR102310697B1
(ko)
|
2012-11-20 |
2021-10-12 |
스펙트럼 파마슈티컬즈 인크 |
치료적 사용을 위한 리포솜 캡슐화 빈크리스틴을 제조하기 위한 개선된 방법
|
CN104854242B
(zh)
|
2012-12-05 |
2018-03-16 |
阿尔尼拉姆医药品有限公司 |
PCSK9 iRNA组合物及其使用方法
|
WO2014089486A1
(en)
|
2012-12-07 |
2014-06-12 |
Shire Human Genetic Therapies, Inc. |
Lipidic nanoparticles for mrna delivering
|
EP2941269B1
(de)
|
2013-01-07 |
2020-12-09 |
Mucosal Vaccine Technologies LLC |
Therapeutische impfstoffe zur behandlung von herpes-simplex-virus-typ 2-infektionen
|
AU2014236156C1
(en)
|
2013-03-14 |
2020-12-17 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating Tau expression
|
US20160184458A1
(en)
|
2013-03-14 |
2016-06-30 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
CN114015692A
(zh)
|
2013-03-14 |
2022-02-08 |
阿尔尼拉姆医药品有限公司 |
补体组分C5 iRNA组合物及其使用方法
|
KR20210122917A
(ko)
|
2013-03-14 |
2021-10-12 |
샤이어 휴먼 지네틱 테라피즈 인크. |
Cftr mrna 조성물 및 관련 방법 및 사용
|
KR20150128687A
(ko)
|
2013-03-14 |
2015-11-18 |
샤이어 휴먼 지네틱 테라피즈 인크. |
메신저 rna의 정제 방법
|
RS57316B1
(sr)
|
2013-03-15 |
2018-08-31 |
Translate Bio Inc |
Sinergističko poboljšanje isporuke nukleinskih kiselina pomoću mešavina formulacija
|
US9937231B2
(en)
|
2013-03-27 |
2018-04-10 |
The General Hospital Corporation |
Methods and agents for treating Alzheimer's disease
|
WO2014182661A2
(en)
|
2013-05-06 |
2014-11-13 |
Alnylam Pharmaceuticals, Inc |
Dosages and methods for delivering lipid formulated nucleic acid molecules
|
EP2999786A1
(de)
|
2013-05-22 |
2016-03-30 |
Alnylam Pharmaceuticals, Inc. |
Tmprss6-irna-zusammensetzungen und verfahren zur verwendung davon
|
HUE038146T2
(hu)
|
2013-05-22 |
2018-09-28 |
Alnylam Pharmaceuticals Inc |
Serpina1 IRNS készítmények és eljárások alkalmazásukra
|
WO2015006228A1
(en)
|
2013-07-08 |
2015-01-15 |
The University Of Utah Research Foundation |
Methods for treatment of and prophylaxis against inflammatory disorders
|
TWI657819B
(zh)
|
2013-07-19 |
2019-05-01 |
美商Ionis製藥公司 |
用於調節τ蛋白表現之組合物
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
CN105793423A
(zh)
|
2013-10-02 |
2016-07-20 |
阿尔尼拉姆医药品有限公司 |
用于抑制lect2基因表达的组合物和方法
|
NZ757749A
(en)
|
2013-10-04 |
2022-07-01 |
Icahn School Med Mount Sinai |
Compositions and methods for inhibiting expression of the alas1 gene
|
MX2016005237A
(es)
|
2013-10-22 |
2016-08-12 |
Shire Human Genetic Therapies |
Terapia de acido ribonucleico mensajero para la deficiencia de argininosuccinato sintetasa.
|
EA201992208A1
(ru)
|
2013-10-22 |
2020-07-31 |
Транслейт Био, Инк. |
ЛЕЧЕНИЕ ФЕНИЛКЕТОНУРИИ С ПРИМЕНЕНИЕМ мРНК
|
WO2015086828A1
(en)
|
2013-12-12 |
2015-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the prevention and treatment of diabetic cardiomyopathy using mir-424/322
|
CA3107872A1
(en)
|
2013-12-12 |
2015-06-18 |
Alnylam Pharmaceuticals, Inc. |
Complement component irna compositions and methods of use thereof
|
US9068179B1
(en)
|
2013-12-12 |
2015-06-30 |
President And Fellows Of Harvard College |
Methods for correcting presenilin point mutations
|
EA201691587A1
(ru)
|
2014-02-11 |
2017-01-30 |
Элнилэм Фармасьютикалз, Инк. |
КОМПОЗИЦИИ НА ОСНОВЕ iRNA ДЛЯ КЕТОГЕКСОКИНАЗЫ (KHK) И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
|
WO2015164773A1
(en)
|
2014-04-25 |
2015-10-29 |
Shire Human Genetic Therapies, Inc. |
Methods for purification of messenger rna
|
SG11201609376SA
(en)
|
2014-05-22 |
2016-12-29 |
Alnylam Pharmaceuticals Inc |
Angiotensinogen (agt) irna compositions and methods of use thereof
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
WO2016033424A1
(en)
|
2014-08-29 |
2016-03-03 |
Genzyme Corporation |
Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
|
SG10201912591RA
(en)
|
2014-09-03 |
2020-02-27 |
Boehringer Ingelheim Int |
Compound targeting il-23a and tnf-alpha and uses thereof
|
KR20170054429A
(ko)
|
2014-09-03 |
2017-05-17 |
제네세규스 인코포레이티드 |
치료용 나노입자 및 관련 조성물, 방법, 및 시스템
|
EP3191591A1
(de)
|
2014-09-12 |
2017-07-19 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete polynukleotidwirkstoffe und verfahren zur verwendung davon
|
JOP20200115A1
(ar)
|
2014-10-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات وطرق لتثبيط التعبير الجيني عن hao1 (حمض أوكسيداز هيدروكسيلي 1 (أوكسيداز جليكولات))
|
EP3207138B1
(de)
|
2014-10-17 |
2020-07-15 |
Alnylam Pharmaceuticals, Inc. |
Gegen aminolävulinsäuresynthase-1 (alas1) gerichtete polynukleotidmittel und verwendungen davon
|
EP3212794B1
(de)
|
2014-10-30 |
2021-04-07 |
Genzyme Corporation |
Polynukleotidwirkstoffe mit abzielung auf serpinc1 (at3) und verfahren zur verwendung davon
|
US9816080B2
(en)
|
2014-10-31 |
2017-11-14 |
President And Fellows Of Harvard College |
Delivery of CAS9 via ARRDC1-mediated microvesicles (ARMMs)
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
WO2016081444A1
(en)
|
2014-11-17 |
2016-05-26 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
|
TW201702218A
(zh)
|
2014-12-12 |
2017-01-16 |
美國杰克森實驗室 |
關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
|
AU2015364508A1
(en)
|
2014-12-18 |
2017-07-06 |
Alnylam Pharmaceuticals, Inc. |
ReversirTM compounds
|
EP3247386A4
(de)
|
2015-01-20 |
2018-10-03 |
The Children's Medical Center Corporation |
Anti-net-verbindungen zur behandlung und prävention von fibrose und wundheilungsförderung
|
CA2976445A1
(en)
|
2015-02-13 |
2016-08-18 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
US10487324B2
(en)
|
2015-02-25 |
2019-11-26 |
Washington University |
Methods to detect motor neuron disease comprising micro-RNAs
|
US10302629B2
(en)
|
2015-03-30 |
2019-05-28 |
University Of Maryland, Baltimore |
Compositions and methods for treating cancer by rational targeting of protein translation
|
US10745702B2
(en)
|
2015-04-08 |
2020-08-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the LECT2 gene
|
CN108271386B
(zh)
|
2015-05-06 |
2022-07-15 |
阿尔尼拉姆医药品有限公司 |
因子XII(哈格曼因子)(F12)、激肽释放酶B、血浆(夫列契因子)1(KLKB1)和激肽原1(KNG1)iRNA组合物及其使用方法
|
EP3307316A1
(de)
|
2015-06-12 |
2018-04-18 |
Alnylam Pharmaceuticals, Inc. |
Gegen komplementkomponente c5 gerichtete irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2016205323A1
(en)
|
2015-06-18 |
2016-12-22 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotde agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
|
WO2016209862A1
(en)
|
2015-06-23 |
2016-12-29 |
Alnylam Pharmaceuticals, Inc. |
Glucokinase (gck) irna compositions and methods of use thereof
|
CN108024535A
(zh)
|
2015-07-02 |
2018-05-11 |
大塚制药株式会社 |
冻干药物组合物
|
US10494632B2
(en)
|
2015-07-10 |
2019-12-03 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
|
JP2018520683A
(ja)
|
2015-07-17 |
2018-08-02 |
アルニラム ファーマスーティカルズ インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
多標的単一体コンジュゲート
|
TWI678213B
(zh)
|
2015-07-22 |
2019-12-01 |
美商史倍壯製藥公司 |
用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
|
US10280231B2
(en)
|
2015-07-23 |
2019-05-07 |
Boehringer Ingelheim International Gmbh |
Compound targeting IL-23A and B-cell activating factor (BAFF) and uses thereof
|
EP3344769B1
(de)
|
2015-09-02 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Programmed cell death 1 ligand 1 (pd-l1) irna-kompositionen und methoden zu deren verwendung
|
TW201718857A
(zh)
|
2015-09-14 |
2017-06-01 |
艾爾妮蘭製藥公司 |
用於抑制alas1基因表現之組合物及方法
|
WO2017048620A1
(en)
|
2015-09-14 |
2017-03-23 |
Alnylam Pharmaceuticals, Inc. |
Polynucleotide agents targeting patatin-like phospholipase domain containing 3 (pnpla3) and methods of use thereof
|
IL258821B
(en)
|
2015-10-23 |
2022-07-01 |
Harvard College |
Nucleobase editors and their uses
|
EP3387129A1
(de)
|
2015-12-10 |
2018-10-17 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen aus sterolregulatorischem element-bindendem protein (srep) chaperone (scap) irna und verfahren zur verwendung davon
|
US10435682B2
(en)
|
2016-02-19 |
2019-10-08 |
University Of South Florida |
Arginine deiminase gene therapy for disordered proteins
|
IL263058B2
(en)
|
2016-06-08 |
2023-11-01 |
Childrens Medical Center |
Engineered botulinum neurotoxins
|
US20190256845A1
(en)
|
2016-06-10 |
2019-08-22 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
FI3481852T3
(fi)
|
2016-07-08 |
2023-03-19 |
Childrens Medical Center |
Uusi botulinum-neurotoksiini ja sen johdannaisia
|
KR102547316B1
(ko)
|
2016-08-03 |
2023-06-23 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
WO2018053142A2
(en)
|
2016-09-14 |
2018-03-22 |
President And Fellows Of Harvard College |
Methods and compositions for modulating erythropoiesis
|
JOP20190065A1
(ar)
|
2016-09-29 |
2019-03-28 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن tau
|
EP3518981A4
(de)
|
2016-10-03 |
2020-06-10 |
President and Fellows of Harvard College |
Abgabe von therapeutischen rnas über arrdc1-vermittelte mikrovesikel
|
KR102622411B1
(ko)
|
2016-10-14 |
2024-01-10 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
핵염기 에디터의 aav 전달
|
TWI788312B
(zh)
|
2016-11-23 |
2023-01-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子A1 iRNA組成物及其使用方法
|
WO2018112320A1
(en)
|
2016-12-16 |
2018-06-21 |
Alnylam Pharmaceuticals, Inc. |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
KR102569848B1
(ko)
|
2016-12-23 |
2023-08-25 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
Pcsk9의 유전자 편집
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
EP3585417B1
(de)
|
2017-02-27 |
2023-02-22 |
Translate Bio, Inc. |
Methode der herstellung von codon-optimierter cftr-mrna
|
WO2018165504A1
(en)
|
2017-03-09 |
2018-09-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
US11542496B2
(en)
|
2017-03-10 |
2023-01-03 |
President And Fellows Of Harvard College |
Cytosine to guanine base editor
|
GB2575930A
(en)
|
2017-03-23 |
2020-01-29 |
Harvard College |
Nucleobase editors comprising nucleic acid programmable DNA binding proteins
|
BR112019021852A2
(pt)
|
2017-04-18 |
2020-06-02 |
Alnylam Pharmaceuticals, Inc. |
Agente de rnai e uma vacina contra hbv, uso ou método e kit para tratamento
|
WO2018204918A1
(en)
|
2017-05-05 |
2018-11-08 |
Ardelyx, Inc. |
Treatment of hepatic disorders
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
WO2018213476A1
(en)
|
2017-05-16 |
2018-11-22 |
Translate Bio, Inc. |
Treatment of cystic fibrosis by delivery of codon-optimized mrna encoding cftr
|
CA3061752A1
(en)
|
2017-07-06 |
2019-01-10 |
Arrowhead Pharmaceuticals, Inc. |
Rnai agents for inhibiting expression of alpha-enac and methods of use
|
JP2020534795A
(ja)
|
2017-07-28 |
2020-12-03 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
ファージによって支援される連続的進化(pace)を用いて塩基編集因子を進化させるための方法および組成物
|
EP3661522A2
(de)
|
2017-08-03 |
2020-06-10 |
Otsuka Pharmaceutical Co., Ltd. |
Arzneimittelverbindung und reinigungsverfahren dafür
|
EP3676376A2
(de)
|
2017-08-30 |
2020-07-08 |
President and Fellows of Harvard College |
Hocheffiziente baseneditoren mit gam
|
CN112105379A
(zh)
|
2017-09-29 |
2020-12-18 |
儿童医学中心公司 |
神经毒素样毒素及其用途
|
WO2019079347A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
USES OF BASIC EDITORS ADENOSINE
|
CA3078971A1
(en)
|
2017-11-01 |
2019-05-09 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof
|
EP3714054A1
(de)
|
2017-11-20 |
2020-09-30 |
Alnylam Pharmaceuticals, Inc. |
Serum-amyloid p-komponente (apcs) irna zusammensetzungen und verfahren zu deren verwendung
|
US10538553B2
(en)
|
2018-01-05 |
2020-01-21 |
University Of South Florida |
Compounds for the treatment of neurodegenerative diseases
|
US20220307001A1
(en)
|
2018-02-27 |
2022-09-29 |
President And Fellows Of Harvard College |
Evolved cas9 variants and uses thereof
|
US10507226B1
(en)
|
2018-05-02 |
2019-12-17 |
University Of South Florida |
N-amino peptide beta-sheet mimics for the treatment of Alzheimer's disease
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
EP3837367A1
(de)
|
2018-08-16 |
2021-06-23 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der lect2-genexpression
|
MA53443A
(fr)
*
|
2018-08-24 |
2021-12-01 |
Flagship Pioneering Innovations Vi Llc |
Paquets de messagers végétaux modifiés et utilisations associées
|
CN112930396A
(zh)
|
2018-08-24 |
2021-06-08 |
川斯勒佰尔公司 |
用于纯化信使rna的方法
|
WO2020051360A1
(en)
|
2018-09-05 |
2020-03-12 |
The Broad Institute, Inc. |
Base editing for treating hutchinson-gilford progeria syndrome
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2020076173A1
(en)
|
2018-09-21 |
2020-04-16 |
Universidade De Coimbra |
Nanodelivery tissue targeting at low systemic exposures and methods thereof
|
US20220389395A1
(en)
|
2018-10-29 |
2022-12-08 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
US10913951B2
(en)
|
2018-10-31 |
2021-02-09 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
|
WO2020102659A1
(en)
|
2018-11-15 |
2020-05-22 |
The Broad Institute, Inc. |
G-to-t base editors and uses thereof
|
JP2022513159A
(ja)
|
2018-11-29 |
2022-02-07 |
フラッグシップ パイオニアリング イノベーションズ ブイ, インコーポレイテッド |
Rnaを調節する方法
|
JP2022515744A
(ja)
|
2018-12-20 |
2022-02-22 |
プラクシス プレシジョン メディシンズ, インコーポレイテッド |
Kcnt1関連障害の治療のための組成物及び方法
|
WO2020181178A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through thymine alkylation
|
WO2020181202A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to t:a base editing through adenine deamination and oxidation
|
WO2020181193A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenosine methylation
|
WO2020181180A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
A:t to c:g base editors and uses thereof
|
WO2020181195A1
(en)
|
2019-03-06 |
2020-09-10 |
The Broad Institute, Inc. |
T:a to a:t base editing through adenine excision
|
CN114040799A
(zh)
|
2019-03-12 |
2022-02-11 |
哈佛大学校长及研究员协会 |
治疗癌症的方法和组合物
|
WO2020191249A1
(en)
|
2019-03-19 |
2020-09-24 |
The Broad Institute, Inc. |
Methods and compositions for editing nucleotide sequences
|
WO2020210751A1
(en)
|
2019-04-12 |
2020-10-15 |
The Broad Institute, Inc. |
System for genome editing
|
EP3956349A1
(de)
|
2019-04-17 |
2022-02-23 |
The Broad Institute, Inc. |
Adeninbaseneditoren mit reduzierten off-target-effekten
|
EP3956474A1
(de)
|
2019-04-18 |
2022-02-23 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Verfahren zur behandlung und prognose von krebs
|
EP3973054A1
(de)
|
2019-05-20 |
2022-03-30 |
The Broad Institute Inc. |
Aav-abgabe von nukleobasen-editoren
|
US20220226269A1
(en)
|
2019-06-12 |
2022-07-21 |
President And Fellows Of Harvard College |
Methods and compositions for modulation of an interspecies gut bacterial pathway for levodopa metabolism
|
US20220315906A1
(en)
|
2019-08-08 |
2022-10-06 |
The Broad Institute, Inc. |
Base editors with diversified targeting scope
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2021030666A1
(en)
|
2019-08-15 |
2021-02-18 |
The Broad Institute, Inc. |
Base editing by transglycosylation
|
EP4025694A1
(de)
|
2019-09-03 |
2022-07-13 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zum hemmen der lect2-genexpression
|
US20230279373A1
(en)
|
2019-09-09 |
2023-09-07 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
WO2021067747A1
(en)
|
2019-10-04 |
2021-04-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
WO2021072328A1
(en)
|
2019-10-10 |
2021-04-15 |
The Broad Institute, Inc. |
Methods and compositions for prime editing rna
|
AR120341A1
(es)
|
2019-11-01 |
2022-02-09 |
Alnylam Pharmaceuticals Inc |
COMPOSICIONES DE AGENTES DE ARNi CONTRA LA HUNTINGTINA (HTT) Y SUS MÉTODOS DE USO
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
EP4061945A1
(de)
|
2019-11-22 |
2022-09-28 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3)-rnai-wirkstoffzusammensetzungen und verfahren zu deren verwendung
|
WO2021108717A2
(en)
|
2019-11-26 |
2021-06-03 |
The Broad Institute, Inc |
Systems and methods for evaluating cas9-independent off-target editing of nucleic acids
|
CA3162908A1
(en)
|
2019-12-03 |
2021-06-10 |
Beam Therapeutics Inc. |
Synthetic guide rna, compositions, methods, and uses thereof
|
WO2021119226A1
(en)
|
2019-12-13 |
2021-06-17 |
Alnylam Pharmaceuticals, Inc. |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
EP4097124A1
(de)
|
2020-01-28 |
2022-12-07 |
The Broad Institute Inc. |
Baseneditoren, zusammensetzungen und verfahren zur modifizierung des mitochondrialen genoms
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
US20230108687A1
(en)
|
2020-02-05 |
2023-04-06 |
The Broad Institute, Inc. |
Gene editing methods for treating spinal muscular atrophy
|
WO2021158921A2
(en)
|
2020-02-05 |
2021-08-12 |
The Broad Institute, Inc. |
Adenine base editors and uses thereof
|
WO2021163066A1
(en)
|
2020-02-10 |
2021-08-19 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing vegf-a expression
|
WO2021178607A1
(en)
|
2020-03-05 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
TW202204615A
(zh)
|
2020-03-26 |
2022-02-01 |
美商阿尼拉製藥公司 |
冠狀病毒iRNA組成物及其使用方法
|
WO2021202443A2
(en)
|
2020-03-30 |
2021-10-07 |
Alnylam Pharmaceucticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
EP4133078A1
(de)
|
2020-04-06 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur ausschaltung der myoc-expression
|
TW202204617A
(zh)
|
2020-04-07 |
2022-02-01 |
美商艾爾妮蘭製藥公司 |
用於靜默scn9a表現之組合物及方法
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
EP4133076A1
(de)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Irna-zusammensetzungen aus angiotensin-konvertierendem enzym 2 (ace2) und verfahren zur verwendung davon
|
EP4143319A1
(de)
|
2020-04-27 |
2023-03-08 |
Alnylam Pharmaceuticals, Inc. |
Apolipoprotein e (apoe) irna-wirkstoffzusammensetzungen und verfahren zur verwendung davon
|
WO2021222318A1
(en)
|
2020-04-28 |
2021-11-04 |
The Broad Institute, Inc. |
Targeted base editing of the ush2a gene
|
MX2022014008A
(es)
|
2020-05-08 |
2023-02-09 |
Broad Inst Inc |
Métodos y composiciones para la edición simultánea de ambas cadenas de una secuencia de nucleótidos de doble cadena objetivo.
|
EP4150076A1
(de)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen zur adar-vermittelten bearbeitung von methyl-cpg-bindendem protein 2 (mecp2)
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
WO2021231698A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
WO2021231691A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rsi)
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
WO2021237097A1
(en)
|
2020-05-21 |
2021-11-25 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
US20230285357A1
(en)
|
2020-05-27 |
2023-09-14 |
The Regents Of The University Of California |
Compositions and methods for transdifferentiating cells
|
US11408000B2
(en)
|
2020-06-03 |
2022-08-09 |
Triplet Therapeutics, Inc. |
Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
|
EP4162050A1
(de)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai-zusammensetzungen und verfahren zur verwendung davon zur verabreichung durch inhalation
|
EP4179091A1
(de)
|
2020-07-10 |
2023-05-17 |
Institut National De La Sante Et De La Recherche Medicale - Inserm |
Verfahren und zusammensetzungen zur behandlung von epilepsie
|
WO2022056454A2
(en)
|
2020-09-14 |
2022-03-17 |
President And Fellows Of Harvard College |
Methods and compositions for treating hpv-positive cancers
|
EP4213947A2
(de)
|
2020-09-16 |
2023-07-26 |
President and Fellows of Harvard College |
Verfahren zur behandlung einer person mit fehlgeschlagener anti-pd-1/anti-pd-l1-therapie
|
EP4217489A1
(de)
|
2020-09-24 |
2023-08-02 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidylpeptidase 4 (dpp4)-irna-zusammensetzungen und verfahren zur verwendung davon
|
JP2023544413A
(ja)
|
2020-10-05 |
2023-10-23 |
アルナイラム ファーマシューティカルズ, インコーポレイテッド |
Gタンパク質共役受容体75(GPR75)iRNA組成物およびその使用方法
|
EP4232581A1
(de)
|
2020-10-21 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur behandlung von primärer hyperoxalurie
|
EP4232582A1
(de)
|
2020-10-23 |
2023-08-30 |
Alnylam Pharmaceuticals, Inc. |
Mucin-5b (muc5b)-irna-zusammensetzungen und verfahren zur verwendung davon
|
WO2022094051A2
(en)
|
2020-10-28 |
2022-05-05 |
Children's Medical Center Corporation |
Truncated modified recombinant adamts13 and uses thereof
|
EP4256053A1
(de)
|
2020-12-01 |
2023-10-11 |
Alnylam Pharmaceuticals, Inc. |
Verfahren und zusammensetzungen zur hemmung der hao1 (hydroxysäureoxidase 1 (glycolatoxidase))-genexpression
|
US11033495B1
(en)
|
2021-01-22 |
2021-06-15 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11357727B1
(en)
|
2021-01-22 |
2022-06-14 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
US11278494B1
(en)
|
2021-01-22 |
2022-03-22 |
Pacira Pharmaceuticals, Inc. |
Manufacturing of bupivacaine multivesicular liposomes
|
CA3210763A1
(en)
|
2021-02-12 |
2022-08-18 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
JP2024507533A
(ja)
|
2021-02-19 |
2024-02-20 |
ビーム・セラピューティクス・インコーポレイテッド |
遺伝子治療のための組み換え狂犬病ウイルス
|
EP4298220A1
(de)
|
2021-02-25 |
2024-01-03 |
Alnylam Pharmaceuticals, Inc. |
Prionprotein (prnp)-irna-zusammensetzungen und verfahren zur verwendung davon
|
EP4305169A1
(de)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glykogensynthasekinase-3-alpha (gsk3a)-irna-zusammensetzungen und verfahren zur verwendung davon
|
AU2022245243A1
(en)
|
2021-03-23 |
2023-09-28 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
KR20230162024A
(ko)
|
2021-03-29 |
2023-11-28 |
알닐람 파마슈티칼스 인코포레이티드 |
헌팅틴(HTT) iRNA 제제 조성물 및 이의 사용 방법
|
KR20240007651A
(ko)
|
2021-04-16 |
2024-01-16 |
빔 테라퓨틱스, 인크. |
간세포의 유전적 변형
|
WO2022232343A1
(en)
|
2021-04-29 |
2022-11-03 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
WO2022245583A1
(en)
|
2021-05-18 |
2022-11-24 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
EP4341405A1
(de)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Verfahren und zusammensetzungen für adar-vermittelte bearbeitung
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
WO2022256578A2
(en)
|
2021-06-02 |
2022-12-08 |
Beam Therapeutics Inc. |
Circular guide rnas for crispr/cas editing systems
|
AR126000A1
(es)
|
2021-06-04 |
2023-08-30 |
Alnylam Pharmaceuticals Inc |
Agentes de arni del marco de lectura abierto 72 del cromosoma 9 humano (c9orf72), composiciones y métodos de uso de los mismos
|
WO2022261509A1
(en)
|
2021-06-11 |
2022-12-15 |
The Broad Institute, Inc. |
Improved cytosine to guanine base editors
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
WO2023283403A2
(en)
|
2021-07-09 |
2023-01-12 |
Alnylam Pharmaceuticals, Inc. |
Bis-rnai compounds for cns delivery
|
WO2023004409A1
(en)
|
2021-07-23 |
2023-01-26 |
Beam Therapeutics Inc. |
Guide rnas for crispr/cas editing systems
|
KR20240037293A
(ko)
|
2021-07-23 |
2024-03-21 |
알닐람 파마슈티칼스 인코포레이티드 |
베타-카테닌(CTNNB1) iRNA 조성물 및 이의 사용 방법
|
AU2022343725A1
(en)
|
2021-09-08 |
2024-03-21 |
Beam Therapeutics Inc. |
Viral guide rna delivery
|
CA3234835A1
(en)
|
2021-10-22 |
2023-04-27 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
WO2023076898A1
(en)
|
2021-10-25 |
2023-05-04 |
The Broad Institute, Inc. |
Methods and compositions for editing a genome with prime editing and a recombinase
|
WO2023076450A2
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
WO2023081756A1
(en)
|
2021-11-03 |
2023-05-11 |
The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone |
Precise genome editing using retrons
|
WO2023094435A1
(en)
|
2021-11-23 |
2023-06-01 |
Cellectis Sa |
New tale protein scaffolds with improved on-target/off-target activity ratios
|
WO2023102538A1
(en)
|
2021-12-03 |
2023-06-08 |
The Broad Institute, Inc. |
Self-assembling virus-like particles for delivery of prime editors and methods of making and using same
|
WO2023102537A2
(en)
|
2021-12-03 |
2023-06-08 |
The Broad Institute, Inc. |
Self-assembling virus-like particles for delivery of nucleic acid programmable fusion proteins and methods of making and using same
|
WO2023114953A2
(en)
|
2021-12-17 |
2023-06-22 |
Beam Therapeutics Inc. |
Novel crispr enzymes, methods, systems and uses thereof
|
WO2023122762A1
(en)
|
2021-12-22 |
2023-06-29 |
Camp4 Therapeutics Corporation |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory rnas
|
WO2023141314A2
(en)
|
2022-01-24 |
2023-07-27 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
WO2023150181A1
(en)
|
2022-02-01 |
2023-08-10 |
President And Fellows Of Harvard College |
Methods and compositions for treating cancer
|
WO2023196772A1
(en)
|
2022-04-04 |
2023-10-12 |
Beam Therapeutics Inc. |
Novel rna base editing compositions, systems, methods and uses thereof
|
WO2023196802A1
(en)
|
2022-04-04 |
2023-10-12 |
The Broad Institute, Inc. |
Cas9 variants having non-canonical pam specificities and uses thereof
|
WO2023205687A1
(en)
|
2022-04-20 |
2023-10-26 |
The Broad Institute, Inc. |
Improved prime editing methods and compositions
|
WO2023212715A1
(en)
|
2022-04-28 |
2023-11-02 |
The Broad Institute, Inc. |
Aav vectors encoding base editors and uses thereof
|
WO2023230613A1
(en)
|
2022-05-27 |
2023-11-30 |
The Broad Institute, Inc. |
Improved mitochondrial base editors and methods for editing mitochondrial dna
|
WO2023240137A1
(en)
|
2022-06-08 |
2023-12-14 |
The Board Institute, Inc. |
Evolved cas14a1 variants, compositions, and methods of making and using same in genome editing
|
WO2023240277A2
(en)
|
2022-06-10 |
2023-12-14 |
Camp4 Therapeutics Corporation |
Methods of modulating progranulin expression using antisense oligonucleotides targeting regulatory rnas
|
WO2024040083A1
(en)
|
2022-08-16 |
2024-02-22 |
The Broad Institute, Inc. |
Evolved cytosine deaminases and methods of editing dna using same
|
WO2024059165A1
(en)
|
2022-09-15 |
2024-03-21 |
Alnylam Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
WO2024059791A1
(en)
|
2022-09-16 |
2024-03-21 |
Beam Therapeutics Inc. |
Large serine recombinases, systems and uses thereof
|
WO2024077267A1
(en)
|
2022-10-07 |
2024-04-11 |
The Broad Institute, Inc. |
Prime editing methods and compositions for treating triplet repeat disorders
|